Rice Hall James & Associates LLC Has $2.13 Million Stock Position in Icon Plc $ICLR

Rice Hall James & Associates LLC lifted its stake in Icon Plc (NASDAQ:ICLR) by 434.9% during the 3rd quarter, Holdings Channel reports. The firm owned 12,163 shares of the medical research company’s stock after acquiring an additional 9,889 shares during the period. Rice Hall James & Associates LLC’s holdings in Icon were worth $2,129,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Private Trust Co. NA lifted its stake in Icon by 200.0% in the third quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock valued at $25,000 after buying an additional 94 shares during the period. Ameritas Advisory Services LLC acquired a new stake in shares of Icon in the 2nd quarter valued at approximately $48,000. LRI Investments LLC bought a new position in Icon during the 2nd quarter worth approximately $49,000. Blue Trust Inc. grew its holdings in Icon by 44.0% during the second quarter. Blue Trust Inc. now owns 393 shares of the medical research company’s stock valued at $57,000 after purchasing an additional 120 shares during the period. Finally, Caitong International Asset Management Co. Ltd grew its holdings in Icon by 40,800.0% during the second quarter. Caitong International Asset Management Co. Ltd now owns 409 shares of the medical research company’s stock valued at $59,000 after purchasing an additional 408 shares during the period. Institutional investors own 95.61% of the company’s stock.

Icon Trading Down 0.5%

ICLR opened at $182.84 on Friday. The stock has a market capitalization of $14.77 billion, a P/E ratio of 24.74, a P/E/G ratio of 3.39 and a beta of 1.25. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. Icon Plc has a 12 month low of $125.10 and a 12 month high of $228.29. The firm’s fifty day simple moving average is $175.36 and its 200 day simple moving average is $169.89.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Barclays lifted their price target on shares of Icon from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Monday, December 15th. Zacks Research raised Icon from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 25th. Cowen reiterated a “hold” rating on shares of Icon in a report on Friday, October 24th. BMO Capital Markets began coverage on Icon in a research note on Thursday, November 13th. They issued a “market perform” rating and a $175.00 target price for the company. Finally, TD Cowen lowered their price target on Icon from $183.00 to $172.00 and set a “hold” rating for the company in a report on Friday, October 24th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $205.31.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.